EPIDAREX CAPITAL ANNOUNCES FIRST CLOSE OF FUND IV, SECURING $145 MILLION TO BUILD NEXT WAVE OF LIFE SCIENCE START-UPS

Core Insights - Epidarex Capital has announced the first close of its Fund IV, securing over $145 million in commitments to support the development of therapeutics and medical device companies [1][2]. Investment Strategy - The Fund's initial investors include notable entities such as the British Business Bank, Strathclyde Pension Fund, and the Scottish National Investment Bank, along with various family offices and international investors [2]. - Epidarex aims to invest in high-quality early-stage healthcare innovations based on breakthrough science in the UK and the US, creating new opportunities for researchers and entrepreneurs [2][3]. Focus Areas - The firm targets major unmet disease needs in areas such as oncology, cardiometabolic, autoimmune, and neurological conditions, leveraging research from established and emerging hubs in the UK and US [3]. - Epidarex's strategy involves leading early-stage financings to bridge the equity funding gap and build globally competitive companies [3]. Portfolio and Impact - Epidarex Capital IV is expected to invest in up to 15 companies, focusing on building high-performance leadership teams and guiding companies through critical development milestones [3][4]. - The firm's existing portfolio includes companies like Apellis Pharmaceuticals and Kynos Therapeutics, showcasing its ability to create companies with strategic value and improve health outcomes [4]. Market Outlook - The Managing Partner of Epidarex believes the next three years present a favorable investment window for biotech innovation, emphasizing the importance of funding for standout innovators [4]. - The British Business Bank is committed to increasing investments in UK life sciences, recognizing the sector as a key growth area within the UK Industrial Strategy [4].